ACADIA Pharma (ACAD) Price Level
Report on Pharma level pricing and FDA approval for ACADIA (ACAD)
Hamden, CT, April 1, 2016 (Newswire.com) - Clark Point Capital, LLC has a price mark of 27.76 for ACADIA Pharmaceuticals (stock listing: ACAD). With market expectations seeking profits in rarefied opportunities, upwards of mid 29. Over a two week span, the holding is a SELL in the 30's. Excess capacity is steering US market away from European risk, and capitalization remains at large. Earnings season should be more readily accepted.
Market expectations seeking profits in rarefied opportunities
Clark Point Capital, LLC
The company must show earnings growth and verify distribution channels more clearly. Expectations for partnerships are not yet substantiated, leaving peripheral businesses in need of capital. Expect market volatility to seek outliers with exceptional force, providing leverage to large cap firms in the future.
Share: